COVID-19 mRNA vaccine allergy.
Curr Opin Pediatr
; 33(6): 610-617, 2021 12 01.
Article
Dans Anglais
| MEDLINE | ID: covidwho-2325853
ABSTRACT
PURPOSE OF REVIEW A known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine is the only contraindication to coronavirus disease 2019 (COVID-19) mRNA vaccination. It is important for pediatricians to understand the likelihood of an allergic reaction to COVID-19 mRNA vaccines, including its excipients. RECENT FINDINGS:
Episodes concerning for anaphylaxis were immediately reported following early administration of COVID-19 mRNA vaccines to adults. Although allergic type symptoms were reported equally in recipients of placebos and test vaccines in phase 3 clinical trials, post-authorization prospective studies state that 0.2-2% of vaccine recipients have experienced allergic reactions. Subsequent allergy testing of affected individuals has focused largely on evaluation of allergic sensitization to a novel vaccine excipient, polyethylene glycol (PEG). PEG is a polymer incorporated in numerous pharmaceutical products because of its favorable, inert properties. The results of allergy testing in adults to date indicate that IgE mediated anaphylaxis to PEG allergy is rarely identified after COVID-19 mRNA vaccine reactions. Numerous individuals with presumed anaphylaxis have tolerated a second vaccine after evaluation and testing by an allergist, suggesting either misdiagnosis or a novel immune mechanism.SUMMARY:
Confirmed anaphylactic reactions to COVID-19 mRNA vaccines are rare, likely due to a lack of preexisting IgE against the vaccine components, including PEG.
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
COVID-19
/
Anaphylaxie
Type d'étude:
Étude de cohorte
/
Étude diagnostique
/
Études expérimentales
/
Étude observationnelle
/
Étude pronostique
Les sujets:
Vaccins
Limites du sujet:
Adulte
/
Humains
langue:
Anglais
Revue:
Curr Opin Pediatr
Thème du journal:
Pédiatrie
Année:
2021
Type de document:
Article
Pays d'affiliation:
Mop.0000000000001077
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS